All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the European Hematology Association (EHA) 2023 Congress, the Lymphoma Hub spoke to Chan Cheah, Sir Charles Gairdner Hospital, Perth, AU. We asked, What are the treatment options for patients with MCL who relapse after BTKi therapy?
What are the treatment options for patients with MCL who relapse after BTKi therapy?
Outcomes for patients with mantle cell lymphoma (MCL) treated with covalent Bruton's tyrosine kinase inhibitors (BTKi) can be poor, with a median overall survival of 6–12 months. Here, Cheah discusses the benefits and drawbacks of different agents considered for patients with BTKi relapsed/refractory MCL, including chimeric antigen receptor T-cell therapies, non-covalent BTKis, and bi-specific antibodies. Not all these therapies are globally available; therefore, he discusses the importance of enrolling patients with MCL for clinical trials to help develop new treatments.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox